8-K Announcements
6Material company update
May 21, 2026·SEC
Material company update
Mar 11, 2026·SEC
Material company update
Jan 30, 2026·SEC
VYNE Therapeutics Inc.(VYNE)Earnings, Financials & Key Ratios
VYNE•NASDAQ
$0.67
Price updated Jul 6, 2026
AboutVYNE Therapeutics Inc., a pharmaceutical company, focuses on developing various therapeutics for the treatment of immuno-inflammatory conditions. The company develops FCD105, a topical combination foam that has completed Phase III clinical trials for the treatment of moderate-to-severe acne vulgaris; and FMX114, a combination of tofacitinib, which is in Phase IIa preclinical trial for the treatment of mild-to-moderate atopic dermatitis. It is also developing VYN201, a bromodomain and extra-terminal (BET) inhibitor for various immuno-inflammatory diseases, including skin diseases; and VYN202, BET inhibitor compounds that are selective for bromodomain 2. The company was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. VYNE Therapeutics Inc. was founded in 2003 and is based in Bridgewater, New Jersey.Show more
- Revenue$570K+13.8%
- EBITDA-$27M+38.7%
- Net Income-$26M+33.5%
- EPS (Diluted)-0.62+34.0%
- Gross Margin95.96%-4.0%
- EBITDA Margin-4689.82%+46.2%
- Operating Margin-5219.12%+40.1%
- Net Margin-4646.14%+41.6%
- ROE-66.33%-17.2%
VYNE Price & Volume
VYNE Therapeutics Inc. (VYNE) stock price & volume — 10-year historical chart
Loading chart...
Clinical Development Burn Outpaces Revenue Generation
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Contracting
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding exhaustion
Key Thesis Takeaways
- VYNE Therapeutics operates as a high-risk, clinical-stage entity where value is almost entirely dependent on the success of the VYN201 program rather than commercial operations.
- The company faces significant financial headwinds, characterized by a persistent reliance on external capital to fund R&D expenditures that frequently exceed $5 million per quarter.
- Investors should monitor the company's ability to extend its $24.6 million cash runway, as the current trajectory of asset erosion and negative operating margins suggests a precarious path toward long-term viability.
Verdict Logic
the company's reliance on external funding is underscored by a dwindling cash position of $24.6 million as of 2026Q1 and a history of persistent operating losses that have eroded shareholder equity.
VYNE Growth Metrics
VYNE Therapeutics Inc. (VYNE) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-51.39%
3 Years6.12%
TTM-24.96%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM49.15%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM51.13%
Return on Capital
10 Years-20.51%
5 Years-66.84%
3 Years-61.34%
Last Year-74.51%
VYNE Recent Earnings
VYNE Therapeutics Inc. (VYNE) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)●Beat Revenue 4/12 qtrs (33%)
Q2 2026Latest
May 15, 2026Metric
Actual
Est
EPS
$0.08+55.6%
$0.18
Rev
$86,000-57.0%
$200,000
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.28-40.0%
$0.20
Rev
$130,000-25.7%
$175,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.17+10.5%
$0.19
Rev
$169,000+35.2%
$125,000
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.13+43.5%
$0.23
Rev
$69,000-65.5%
$200,000
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 15, 2026 | $0.08vs $0.18+55.6% | $86,000vs $200,000-57.0% |
| Q2 2026 | Mar 12, 2026 | $0.28vs $0.20-40.0% | $130,000vs $175,000-25.7% |
| Q4 2025 | Nov 6, 2025 | $0.17vs $0.19+10.5% | $169,000vs $125,000+35.2% |
| Q3 2025 | Aug 14, 2025 | $0.13vs $0.23+43.5% | $69,000vs $200,000-65.5% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for VYNE Therapeutics Inc. (VYNE)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $0.67 | $28.55M | -1.08 | 13.77% | -4646.14% | -66.33% | — | |
| $7.22 | $198.71M | -15.36 | 10.2% | -14.82% | -35.57% | — | |
| $11.09 | $1.53B | -1.08 | -2.75% | -43.5% | -50.65% | — | |
| $0.75 | $97.84M | -4.72 | -10.02% | -2.03% | -9.41% | — | |
| $2.48 | $319.11M | 16.53 | 16.8% | -0.06% | -0.07% | — | |
| $3.08 | $1.07B | 36.11 | 0.57% | 3.74% | 4.75% | — |
Compare VYNE vs Peers
VYNE Therapeutics Inc. (VYNE) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
VYNE SEC Filings & Documents
VYNE Therapeutics Inc. (VYNE) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when VYNE posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
VYNE Frequently Asked Questions
VYNE Therapeutics Inc. (VYNE) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is VYNE Therapeutics Inc.'s revenue?
VYNE Therapeutics Inc. (VYNE) reported $0.5M in revenue for fiscal year 2025.
How fast is VYNE Therapeutics Inc. growing?
VYNE Therapeutics Inc. (VYNE) grew revenue by 13.8% over the past year. This is steady growth.
Is VYNE profitable?
VYNE Therapeutics Inc. (VYNE) reported a net loss of $21.5M for fiscal year 2025.
Dividend & Returns
What is VYNE's return on equity?
VYNE Therapeutics Inc. (VYNE) has a return on equity (ROE) of -66.3%. Negative ROE indicates the company is unprofitable.
What is VYNE Therapeutics Inc.'s free cash flow?
VYNE Therapeutics Inc. (VYNE) had negative free cash flow of $25.7M in fiscal year 2025, likely due to heavy capital investments.